# Sinovac Biotech Ltd

Sinovac Biotech Ltd is an other based in Beijing, China.

## Overview

- **Organization type:** other
- **Headquarters:** Beijing, China
- **Region:** Asia
- **Address:** Beijing, China
- **Founded:** 2001
- **Assets under management:** Undisclosed
- **Website:** sinovac.com

## Regulatory record

- **Reports private funds:** No

## About

Sinovac Biotech Ltd was founded in 2001 by Weidong Yin, a biologist and entrepreneur who previously worked at China's National Institute for the Control of Pharmaceutical and Biological Products. The company is headquartered in Beijing and develops vaccines for infectious diseases, including hepatitis A and B, influenza, hand-foot-and-mouth disease (EV71), and COVID-19. Sinovac's core asset — its inactivated vaccine platform — underpins its production pipeline (per company filings). Sinovac focuses on whole-virion inactivated virus vaccines, which rely on traditional, well-understood manufacturing processes. Its most recognized product, CoronaVac, received emergency use authorization in over 50 countries starting in 2021, with the World Health Organization (WHO) granting Emergency Use Listing in June 2021. The company also markets vaccines for hepatitis A under the brand Healive and for EV71 (hand, foot, and mouth disease) as Inlive. Sinovac has not publicly disclosed AUM or assets under management, as it is a publicly traded biotech firm, not an investment fund. The firm employs roughly 4,000 people as of late 2023, per its annual report. Its manufacturing network includes facilities in Beijing and Xuzhou, China, with a combined annual production capacity of over one billion doses. Sinovac maintains a philanthropic focus via its charitable initiatives, though separated from its commercial operations. Sinovac's structural differentiator lies in its role as a state-supported yet publicly listed vaccine developer — balancing government procurement contracts (especially for emerging market supply) with Western institutional shareholder demands. Unlike many biotech peers that license technology, Sinovac controls its entire inactivated-vaccine production chain, from viral seed stocks to fill-finish, giving it supply-chain leverage in global health emergencies.

## Sectors

- Healthcare Services

## People

- Weidong Yin — Chairman, President & CEO

## Questions

### Who makes investment decisions at Sinovac?

Sinovac Biotech is a publicly traded company, not a family office. Investment and capital allocation decisions are overseen by Chairman and CEO Weidong Yin, along with the board of directors.

### What is Sinovac's most successful product?

CoronaVac, Sinovac's COVID-19 vaccine, became one of the most widely deployed vaccines during the pandemic, with over 2.6 billion doses delivered globally by mid-2022 (per WHO, 2022).

### Where does the wealth behind Sinovac originate?

Sinovac generates revenue through vaccine sales to government health agencies and international organizations. Revenue of approximately $19.3 billion was reported for fiscal year 2021, reflecting COVID-19 vaccine demand (per company filing, 2022).

### Does Sinovac invest in other biotech companies?

Sinovac primarily reinvests in its own R&D and manufacturing capacity. There are no public records of direct venture investments or fund commitments to external biotech startups.

## Related profiles

- [PPLUS Trust Series GSC-2](https://altss.com/profile/pplus-trust-series-gsc-2)
- [STRATS(SM) TRUST FOR DOMINION RESOURCES, INC. SECURITIES, SERIES 2005-6](https://altss.com/profile/stratssm-trust-for-dominion-resources-inc-securities-series-2005-6)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/sinovac-biotech-ltd

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology